---
title: Antiarrhythmic Drugs
type: content
phase: 1
status: complete
priority: high
tags: [antiarrhythmics, vaughan-williams, class-I-IV, arrhythmias, sodium-channel-blockers, beta-blockers, potassium-channel-blockers, calcium-channel-blockers]
created: 2025-11-08
last_modified: 2025-11-08
---

# Antiarrhythmic Drugs

## Introduction

Cardiac arrhythmias result from abnormalities in impulse generation (automaticity) or impulse conduction (reentry). Antiarrhythmic drugs modify cardiac electrophysiology to prevent or terminate arrhythmias. The Vaughan Williams classification system categorizes these drugs based on their primary mechanism of action.

## Core Concept

Cardiac action potential phases:
- **Phase 0**: Rapid depolarization (Na+ influx)
- **Phase 1**: Early repolarization (K+ efflux)
- **Phase 2**: Plateau (Ca2+ influx, K+ efflux)
- **Phase 3**: Repolarization (K+ efflux)
- **Phase 4**: Resting potential/spontaneous depolarization

Antiarrhythmics target specific ion channels to modify conduction velocity, refractory period, and automaticity.

---

## Vaughan Williams Classification

| Class | Mechanism | Primary Effect | Examples |
|-------|-----------|----------------|----------|
| IA | Moderate Na+ block | ↑APD, ↑QT | Quinidine, Procainamide, Disopyramide |
| IB | Weak Na+ block | ↓APD | Lidocaine, Mexiletine |
| IC | Strong Na+ block | No change APD | Flecainide, Propafenone |
| II | β-blockers | ↓SA/AV node | Metoprolol, Esmolol |
| III | K+ channel block | ↑APD, ↑QT | Amiodarone, Sotalol, Dofetilide, Ibutilide |
| IV | Ca2+ channel block | ↓SA/AV node | Verapamil, Diltiazem |
| Other | Various | Various | Adenosine, Digoxin, Magnesium |

---

## Class I: Sodium Channel Blockers

### General Mechanism

**Action**:
- Block voltage-gated Na+ channels (phase 0)
- Slow depolarization → ↓conduction velocity
- Use-dependent block (more effect at faster rates)

**Effects**:
- ↓Conduction velocity in atria, ventricles, accessory pathways
- Variable effects on action potential duration (APD)
- Variable effects on QRS and QT intervals

### Class IA: Moderate Sodium Channel Block

**Drugs**: Quinidine, Procainamide, Disopyramide

**Mechanism**:
- Moderate Na+ channel blockade
- Also block K+ channels → prolong repolarization
- **Effects**: ↓Conduction velocity, ↑APD, ↑ERP, ↑QRS, ↑QT

#### Quinidine

**Pharmacokinetics**:
- Oral administration
- Hepatic metabolism (CYP3A4)
- t½ = 6-8 hours
- Renal excretion

**Clinical Uses**:
- **Atrial fibrillation** (rhythm control) - rarely used
- **Atrial flutter**
- **Ventricular arrhythmias**
- **Malaria** (quinine, related compound)

**Adverse Effects**:
- **Cinchonism**: Tinnitus, headache, dizziness, visual disturbances
- **Diarrhea** (30% of patients) - common reason for discontinuation
- **QT prolongation** → Torsades de pointes (1-3%)
- **Hypotension** (α-blockade)
- **Thrombocytopenia** (immune-mediated)
- Pro-arrhythmic effects

**Drug Interactions**:
- **Digoxin**: ↑digoxin levels (↓renal clearance)
- **Warfarin**: ↑INR
- **CYP3A4 inhibitors**: ↑quinidine levels

**Contraindications**:
- AV block
- QT prolongation
- Myasthenia gravis (worsens symptoms)
- Thrombocytopenia

#### Procainamide

**Pharmacokinetics**:
- IV or oral
- Hepatic acetylation → NAPA (active metabolite)
- t½ = 3-4 hours (procainamide), 6-8 hours (NAPA)
- Renal excretion

**Clinical Uses**:
- **Wide-complex tachycardia** (stable VT)
- **AF with WPW** (pre-excited AF)
- **Ventricular arrhythmias**
- Acute conversion of AF

**Adverse Effects**:
- **Drug-induced lupus** (50-80% with chronic use)
  - ANA positive in most patients
  - Symptomatic lupus in ~30%
  - Risk factors: Slow acetylators, prolonged use
- **QT prolongation** → Torsades
- **Hypotension** (rapid IV)
- **Agranulocytosis** (rare)
- **GI upset**

**Monitoring**:
- ANA, CBC (if chronic use)
- ECG (QT interval)
- Drug levels (therapeutic: 4-10 mcg/mL)

**Contraindications**:
- Lupus
- Complete heart block
- Torsades de pointes

#### Disopyramide

**Unique Properties**:
- Significant **anticholinergic effects**
- **Negative inotropic effects** (strongest of Class IA)

**Clinical Uses**:
- Ventricular arrhythmias
- **Hypertrophic cardiomyopathy** (negative inotropy beneficial)
- Rarely used due to side effects

**Adverse Effects**:
- **Anticholinergic**: Dry mouth, urinary retention, constipation, blurred vision
- **Negative inotropy** → HF exacerbation
- **QT prolongation**
- **Hypoglycemia** (rare)

**Contraindications**:
- Heart failure
- Glaucoma
- Urinary retention
- Myasthenia gravis

### Class IB: Weak Sodium Channel Block

**Drugs**: Lidocaine, Mexiletine, Phenytoin

**Mechanism**:
- Weak, fast-dissociating Na+ block
- Preferentially affect ischemic/depolarized tissue
- Shorten APD in ventricles
- **Effects**: Minimal ↓conduction velocity, ↓APD, minimal ECG changes

#### Lidocaine

**Pharmacokinetics**:
- **IV only** (high first-pass metabolism, ~70%)
- Hepatic metabolism (CYP3A4, CYP1A2)
- t½ = 1.5-2 hours
- Reduced clearance in: HF, liver disease, elderly

**Clinical Uses**:
- **Ventricular arrhythmias** (VT/VF) - especially post-MI or ischemia
- **No effect on atrial arrhythmias**
- Largely replaced by amiodarone

**Dosing**:
- Loading: 1-1.5 mg/kg IV bolus
- Maintenance: 1-4 mg/min infusion

**Adverse Effects**:
- **CNS toxicity** (dose-related):
  - Paresthesias, drowsiness
  - Confusion, slurred speech
  - Seizures (high levels)
  - Respiratory depression
- **Cardiovascular**: Hypotension, bradycardia (high doses)
- **Less pro-arrhythmic** than other Class I drugs

**Monitoring**:
- ECG, BP
- Neurological status
- Drug levels (therapeutic: 1.5-5 mcg/mL)

**Contraindications**:
- Severe SA or AV block
- Wolff-Parkinson-White syndrome (WPW)

#### Mexiletine

**Unique Features**:
- **Oral analog of lidocaine**
- Used for chronic therapy

**Clinical Uses**:
- Ventricular arrhythmias
- **Myotonic disorders** (off-label)

**Adverse Effects**:
- **GI upset** (30-40%): Nausea, vomiting - take with food
- **CNS**: Tremor, dizziness, ataxia
- **Cardiovascular**: Minimal pro-arrhythmic risk

### Class IC: Strong Sodium Channel Block

**Drugs**: Flecainide, Propafenone

**Mechanism**:
- Potent Na+ channel blockade
- Slow dissociation kinetics
- Markedly slow conduction
- **Effects**: ↓↓Conduction velocity, minimal ↑APD, ↑QRS, minimal QT change

**Clinical Pearl**: **Most pro-arrhythmic** of Class I drugs

#### Flecainide

**Pharmacokinetics**:
- Oral administration
- Hepatic metabolism + renal excretion (50/50)
- t½ = 12-27 hours
- Dose adjustment in renal impairment

**Clinical Uses**:
- **Paroxysmal SVT** (PSVT)
- **Atrial fibrillation** (rhythm control in structurally normal hearts)
- **"Pill-in-the-pocket"** approach for AF
- **Contraindicated**: Structural heart disease, CAD, post-MI

**Adverse Effects**:
- **Pro-arrhythmia** (CAST trial):
  - ↑Mortality in post-MI patients
  - VT/VF risk
- **Negative inotropy** → HF
- **↑QRS duration** (monitor ECG)
- **Visual disturbances**
- **Dizziness**

**CAST Trial**: Cardiac Arrhythmia Suppression Trial
- Showed ↑mortality with flecainide/encainide post-MI
- Limited use to patients WITHOUT structural heart disease

**Contraindications**:
- Coronary artery disease
- Post-MI
- LV dysfunction
- Heart failure
- AV block

**Clinical Use Requirements**:
- Document structurally normal heart (echo)
- No CAD
- Initiate in monitored setting

#### Propafenone

**Unique Properties**:
- Also has **β-blocking activity**
- Weak calcium channel blocking activity

**Pharmacokinetics**:
- Oral administration
- Extensive first-pass metabolism
- CYP2D6 substrate (genetic variability)
- t½ = 2-10 hours (extensive metabolizers), 10-32 hours (poor metabolizers)

**Clinical Uses**:
- Similar to flecainide
- Paroxysmal AF (structurally normal hearts)
- PSVT

**Adverse Effects**:
- Similar to flecainide
- **Pro-arrhythmia**
- **Taste disturbance** (metallic taste)
- **Bronchospasm** (β-blocking activity)

**Contraindications**:
- Same as flecainide
- Asthma/COPD (relative, due to β-blockade)

---

## Class II: Beta-Blockers

### Mechanism of Action

- Competitive β-adrenergic receptor antagonism
- **Primary effects on nodal tissue** (SA and AV nodes)
- ↓Sympathetic stimulation
- ↓Phase 4 slope (↓automaticity)
- ↓AV nodal conduction velocity

### Antiarrhythmic Effects

- ↓Heart rate
- ↑AV nodal refractory period
- ↓Ventricular response in AF/flutter
- Suppress triggered activity
- ↓Myocardial O2 demand

### Commonly Used Agents

**Esmolol**:
- Ultra-short acting (t½ = 9 minutes)
- **IV only**
- Useful for acute rate control
- Titratable

**Metoprolol**:
- β1-selective
- IV or PO
- Common for acute and chronic use

**Propranolol**:
- Non-selective (β1 + β2)
- IV or PO

**Carvedilol, Bisoprolol**:
- Primarily for chronic rate control and HF

### Clinical Indications

**Acute**:
1. **Rate control**: AF, atrial flutter, MAT
2. **Acute MI**: Reduce arrhythmias, reduce mortality
3. **Perioperative**: Prevent arrhythmias
4. **Thyrotoxicosis**: Rate control

**Chronic**:
1. **Rate control**: Chronic AF/flutter
2. **Ventricular arrhythmias**: Especially catecholamine-driven
3. **Long QT syndrome**
4. **Heart failure**: Reduce mortality

### Adverse Effects

- Bradycardia
- AV block
- Hypotension
- Bronchospasm (non-selective agents)
- Fatigue
- Sexual dysfunction
- Mask hypoglycemia

### Contraindications

- Severe bradycardia
- 2nd/3rd degree AV block
- Decompensated HF (acute)
- Severe asthma
- Cocaine-induced MI (unopposed α-stimulation)

### Clinical Pearls

1. **First-line for rate control** in AF
2. **Reduce mortality** in HF and post-MI
3. **Essential in Long QT syndrome**
4. **Use β1-selective** in COPD if needed
5. **Taper when discontinuing** (avoid rebound)

---

## Class III: Potassium Channel Blockers

### Mechanism of Action

- Block K+ channels (primarily IKr)
- Prolong phase 3 repolarization
- **↑Action potential duration**
- **↑Effective refractory period**
- **↑QT interval**

### Risk: Torsades de Pointes

All Class III agents prolong QT → risk of **Torsades de pointes**

**Risk Factors**:
- Female sex
- Hypokalemia
- Hypomagnesemia
- Bradycardia
- Baseline QT prolongation
- Concomitant QT-prolonging drugs
- Heart failure
- LV hypertrophy

#### Amiodarone

**Unique Properties**:
- **Multi-class effects**: I, II, III, IV
- Most effective antiarrhythmic
- Also most toxic with chronic use

**Mechanism**:
- Primarily Class III (K+ block)
- Also: Na+ block, β-block, Ca2+ block
- Non-competitive β-blockade

**Pharmacokinetics**:
- **Very long half-life**: 40-60 days (range 25-100 days)
- Highly lipophilic
- Extensive tissue distribution (Vd = 5000 L)
- Hepatic metabolism
- Takes **months to reach steady state**
- Takes **months to clear** after discontinuation

**Loading Strategies**:
1. **Oral loading**: 400-800 mg daily × 1-3 weeks, then 200-400 mg daily
2. **IV loading**: 150 mg over 10 min, then 1 mg/min × 6 hr, then 0.5 mg/min

**Clinical Uses**:
1. **Ventricular arrhythmias**: VT/VF (drug of choice)
2. **Atrial fibrillation**: Rhythm and rate control
3. **Cardiac arrest**: ACLS algorithm
4. **Wide-complex tachycardia**
5. **Most effective antiarrhythmic** available

**Advantages**:
- Broad spectrum of activity
- Minimal negative inotropy
- Can use in heart failure
- **Least pro-arrhythmic** despite QT prolongation

**Adverse Effects** (very common with chronic use):

**Pulmonary** (5-15%):
- **Pulmonary fibrosis/pneumonitis** (potentially fatal)
- Risk ↑ with doses >400 mg/day
- Monitor: Baseline and annual PFTs, CXR
- Symptoms: Dyspnea, cough, fever
- May be irreversible

**Thyroid** (15-20%):
- Contains **iodine** (37% by weight)
- **Hypothyroidism** (more common)
- **Hyperthyroidism** (more dangerous)
- Monitor: TFTs at baseline, q6 months
- Effects can occur months after discontinuation

**Hepatic** (15-30%):
- Transaminase elevation (common, usually asymptomatic)
- Hepatitis (rare)
- Monitor: LFTs at baseline, q6 months

**Ocular** (>90%):
- **Corneal microdeposits** (nearly universal, usually asymptomatic)
- Optic neuropathy/neuritis (rare, vision loss)
- Photophobia, halos around lights
- Ophthalmologic exam: Baseline, annually

**Dermatologic**:
- **Blue-gray skin discoloration** (chronic use)
- **Photosensitivity** (common)
- Recommend: Sunscreen, protective clothing

**Cardiovascular**:
- **Bradycardia**
- **QT prolongation** (but low TdP risk)
- **Hypotension** (especially IV)
- AV block

**Neurologic**:
- Peripheral neuropathy
- Ataxia, tremor
- Sleep disturbances

**GI**:
- Nausea, anorexia
- Constipation

**Drug Interactions**:
- **Warfarin**: ↑INR (inhibits metabolism, ↓Vit K) - reduce warfarin 30-50%
- **Digoxin**: ↑digoxin levels - reduce digoxin 50%
- **Statins**: ↑statin levels → rhabdomyolysis risk
- **CYP3A4 substrates**: Multiple interactions
- **Other QT-prolonging drugs**: Additive risk

**Monitoring**:
- **Baseline**: TFTs, LFTs, PFTs, CXR, ophthalmologic exam, ECG
- **Periodic**: TFTs q6mo, LFTs q6mo, annual PFTs/CXR, annual eye exam
- ECG for QT (target QTc <500 ms)

**Contraindications**:
- Severe sinus node dysfunction
- 2nd/3rd degree AV block (without pacemaker)
- Cardiogenic shock
- Severe bradycardia

**Clinical Pearls**:
1. **Most effective antiarrhythmic** but most toxic
2. **Reserve for refractory cases** or when other drugs contraindicated
3. **Long half-life**: Takes months to load and clear
4. **Low TdP risk**: Despite QT prolongation (unique among Class III)
5. **Extensive monitoring required**

#### Dronedarone

**Relation to Amiodarone**:
- Derivative of amiodarone (no iodine)
- Developed to have **less toxicity** than amiodarone
- Less effective than amiodarone

**Pharmacokinetics**:
- Shorter half-life: 24-30 hours (vs. 40-60 days for amiodarone)
- Dosed 400 mg BID

**Clinical Uses**:
- **Atrial fibrillation** (paroxysmal or persistent)
- **Not for permanent AF**
- **Not for heart failure** (contraindicated)

**Advantages over Amiodarone**:
- No pulmonary fibrosis
- No thyroid effects (no iodine)
- Shorter half-life
- Less drug interactions

**Adverse Effects**:
- **↑Mortality in permanent AF** (PALLAS trial)
- **↑Mortality in severe HF** (ANDROMEDA trial)
- **Hepatotoxicity** (rare but severe)
- QT prolongation
- GI upset
- Bradycardia

**Contraindications**:
- **NYHA Class IV or recent decompensated HF**
- **Permanent AF** (not paroxysmal/persistent)
- Severe hepatic impairment
- Concomitant strong CYP3A4 inhibitors

**Drug Interactions**:
- Similar to amiodarone but less extensive
- Warfarin, digoxin (increase levels)
- CYP3A4 metabolism

**Clinical Pearl**: Less toxic but also **less effective** than amiodarone; **contraindicated in HF**

#### Sotalol

**Unique Properties**:
- **Class III + Class II** (non-selective β-blocker)
- Dual mechanism

**Pharmacokinetics**:
- Oral administration
- Not metabolized
- **Renal excretion** (100%)
- **Dose adjustment required** in renal impairment
- t½ = 12 hours

**Clinical Uses**:
- Ventricular arrhythmias
- Atrial fibrillation
- AF with WPW

**Adverse Effects**:
- **Torsades de pointes** (2-4%) - highest risk of Class III drugs
  - Risk ↑ with: Renal impairment, QTc >500 ms, female sex, hypokalemia
- **β-blocker effects**: Bradycardia, bronchospasm, fatigue
- Pro-arrhythmic

**Monitoring**:
- **Initiate in hospital** with continuous ECG monitoring
- Monitor QT interval
- Calculate CrCl for dosing
- Check electrolytes

**Contraindications**:
- QT >450 ms (baseline)
- CrCl <40 mL/min (relative)
- Asthma
- Bradycardia, AV block
- HF (relative)

**Clinical Pearl**: Higher TdP risk than amiodarone; requires **in-hospital initiation**

#### Dofetilide

**Mechanism**:
- **Pure Class III** (selective IKr blocker)
- No other cardiac effects

**Pharmacokinetics**:
- Oral administration
- Renal excretion (80%)
- Dose based on CrCl
- t½ = 10 hours

**Clinical Uses**:
- **Atrial fibrillation** (conversion and maintenance)
- Can use in heart failure (unlike many antiarrhythmics)

**Advantages**:
- Can use in HF patients
- Effective for AF

**Adverse Effects**:
- **Torsades de pointes** (1-3%)
  - Highest risk in first 3 days
- QT prolongation
- Headache, dizziness

**Initiation Requirements** (FDA REMS program):
- **Mandatory in-hospital initiation** (minimum 3 days)
- Continuous ECG monitoring
- Calculate CrCl for dosing
- Monitor QT after each dose
- Check electrolytes
- Prescribers must be certified

**Drug Interactions**:
- **Contraindicated with**:
  - Verapamil, cimetidine, ketoconazole, trimethoprim
  - Other QT-prolonging drugs
- Renal cation transport inhibitors increase levels

**Monitoring**:
- QTc after each dose during initiation
- Renal function
- Electrolytes (K+, Mg2+)

**Clinical Pearl**: **REMS program** required; in-hospital initiation mandatory

#### Ibutilide

**Unique Features**:
- **IV only**
- Used for **acute conversion** of AF/flutter

**Pharmacokinetics**:
- IV infusion
- Rapid distribution
- Hepatic metabolism
- t½ = 6 hours

**Clinical Use**:
- **Acute conversion** of atrial fibrillation or atrial flutter
- ~50% efficacy for AF, ~70% for flutter

**Dosing**:
- 1 mg IV over 10 min
- Can repeat once if needed

**Adverse Effects**:
- **Torsades de pointes** (4-8%)
  - Monitor for 4-6 hours post-infusion
- QT prolongation

**Monitoring**:
- Continuous ECG during and 4-6 hours after infusion
- Correct K+ and Mg2+ before use

**Clinical Pearl**: Used for **acute chemical cardioversion**; monitor for TdP

---

## Class IV: Calcium Channel Blockers

### Mechanism of Action

- Block L-type Ca2+ channels
- **Primary effect on nodal tissue** (SA and AV nodes)
- ↓Phase 0 in nodal tissue (Ca2+-dependent)
- ↓AV nodal conduction
- ↑AV nodal refractory period

### Non-Dihydropyridines

**Verapamil** and **Diltiazem** have antiarrhythmic properties

**Dihydropyridines** (amlodipine, nifedipine): No significant antiarrhythmic effect

### Clinical Uses

1. **Rate control**: Atrial fibrillation, atrial flutter
2. **PSVT** (paroxysmal supraventricular tachycardia):
   - Acute termination
   - Prophylaxis
3. **Multifocal atrial tachycardia (MAT)**

### Verapamil

**Pharmacokinetics**:
- IV or PO
- Extensive first-pass metabolism
- t½ = 4-12 hours

**Dosing**:
- IV: 5-10 mg over 2-3 min
- PO: 80-120 mg TID (or ER formulation)

**Adverse Effects**:
- **Constipation** (most common)
- **Negative inotropy** → HF exacerbation
- **Bradycardia**
- **AV block**
- Hypotension

### Diltiazem

**Pharmacokinetics**:
- IV or PO
- Hepatic metabolism
- t½ = 3-7 hours

**Dosing**:
- IV bolus: 0.25 mg/kg over 2 min
- IV infusion: 5-15 mg/hr
- PO: 30-90 mg QID (or ER formulation)

**Adverse Effects**:
- Similar to verapamil but:
- Less constipation
- Less negative inotropy (can use more safely in mild HF)

### Contraindications (Both)

- Severe LV dysfunction
- Hypotension
- Sick sinus syndrome
- 2nd/3rd degree AV block
- **Avoid in AF with WPW** (can precipitate VF)
- Concomitant β-blocker (relative)

### Drug Interactions

- **β-blockers**: Additive bradycardia, AV block, negative inotropy
- **Digoxin**: ↑digoxin levels (especially verapamil)
- **CYP3A4 substrates**: Increase levels

### Clinical Pearls

1. **Alternative to β-blockers** for rate control
2. **First-line for PSVT** (with adenosine)
3. **Diltiazem preferred** in patients with mild LV dysfunction
4. **Contraindicated in WPW with AF**

---

## Uncategorized Antiarrhythmics

### Adenosine

**Mechanism**:
- A1 receptor agonist
- Activates K+ channels → hyperpolarization
- Inhibits cAMP → ↓Ca2+ entry
- **Transient AV nodal blockade**

**Pharmacokinetics**:
- **Ultra-short half-life**: <10 seconds
- Taken up by RBCs and vascular endothelium
- Metabolism by adenosine deaminase

**Clinical Uses**:
- **PSVT** (drug of choice for acute termination)
  - ~90% efficacy for reentrant SVT
- **Diagnostic tool**: Unmask atrial activity (flutter, AT)

**Dosing**:
- 6 mg rapid IV push (over 1-2 seconds)
- If no response: 12 mg
- Can repeat 12 mg once more
- **Must give rapid push** followed by saline flush
- Use large, proximal vein

**Adverse Effects** (transient, seconds):
- **Chest pain/tightness** (very common)
- **Dyspnea** (feeling of "impending doom")
- **Flushing**
- **Transient asystole** (1-15 seconds) - expected
- **Bronchospasm** (asthma patients)

**Contraindications**:
- 2nd/3rd degree AV block
- Sick sinus syndrome
- Severe asthma/COPD (relative)

**Drug Interactions**:
- **Dipyridamole**: ↑adenosine effect (blocks reuptake) - use lower dose
- **Theophylline/caffeine**: ↓adenosine effect (competitive antagonism)

**Clinical Pearls**:
1. **Drug of choice** for acute PSVT
2. **Warn patient**: Will feel chest discomfort
3. **Rapid push essential**: Drug must reach heart before degradation
4. **Safe in WPW** (unlike verapamil/diltiazem)
5. **Diagnostic**: Can reveal underlying atrial rhythm

### Digoxin

**Mechanism**:
- Na+-K+-ATPase inhibitor → ↑intracellular Ca2+
- ↑Vagal tone
- ↓AV nodal conduction
- ↑Contractility (positive inotropy)

**Clinical Uses**:
- **Rate control in AF** (especially with HF)
- **Heart failure** (mild symptom benefit)

**Limitations**:
- Does NOT control rate during exercise
- Narrow therapeutic index
- Numerous drug interactions

**Adverse Effects**:
- Arrhythmias (any type)
- GI: Nausea, anorexia
- Visual: Yellow-green halos (xanthopsia)
- CNS: Confusion, delirium

**Clinical Pearl**: Less commonly used now; reserved for AF with HF

### Magnesium

**Mechanism**:
- Multiple effects on cardiac electrophysiology
- Cofactor for Na+-K+-ATPase
- Stabilizes cardiac membranes

**Clinical Uses**:
- **Torsades de pointes** (drug of choice)
- Refractory VF/VT (ACLS)
- Digoxin toxicity

**Dosing**:
- Torsades: 2 g IV over 5-10 min
- Cardiac arrest: 1-2 g IV push

**Clinical Pearl**: **First-line for Torsades**, even if Mg2+ normal

---

## Clinical Approach to Arrhythmias

### Atrial Fibrillation

**Rate Control** (preferred initial strategy in most):
- β-blockers (metoprolol, esmolol)
- Calcium channel blockers (diltiazem, verapamil)
- Digoxin (with HF)

**Rhythm Control** (selected patients):
- Structurally normal heart: Flecainide, propafenone
- Structural heart disease/HF: Amiodarone, dofetilide
- Consider dronedarone (if not permanent AF, no HF)

### Atrial Flutter

- Similar to AF
- **Catheter ablation** highly effective

### Paroxysmal Supraventricular Tachycardia (PSVT)

**Acute termination**:
1. Vagal maneuvers
2. **Adenosine** (drug of choice)
3. Verapamil or diltiazem (alternative)

**Chronic suppression**:
- β-blockers
- Calcium channel blockers
- **Catheter ablation** (curative in most cases)

### Ventricular Tachycardia

**Stable VT**:
- Amiodarone (first-line)
- Procainamide
- Sotalol
- Lidocaine (if ischemic)

**Unstable VT**:
- **Electrical cardioversion**
- Amiodarone

**Long-term management**:
- β-blockers
- **ICD** (implantable cardioverter-defibrillator) - primary therapy
- Antiarrhythmics: Amiodarone, sotalol (adjunct to ICD)

### Ventricular Fibrillation / Pulseless VT

**ACLS**:
- **Defibrillation** (primary therapy)
- Epinephrine
- Amiodarone or lidocaine

### Torsades de Pointes

1. **Stop offending drug**
2. **Magnesium** 2 g IV (drug of choice)
3. Correct electrolytes (K+, Mg2+)
4. **Increase heart rate** (reduces QT):
   - Isoproterenol infusion
   - Temporary pacing
5. Defibrillation if sustained/unstable

---

## Key Takeaways

1. **Vaughan Williams classification**: Organizes drugs by mechanism (I-IV)
2. **Class IA**: Prolong QT, risk of Torsades
3. **Class IC**: Most pro-arrhythmic, **avoid in structural heart disease** (CAST trial)
4. **Amiodarone**: Most effective, most toxic; multi-class effects
5. **Sotalol, Dofetilide**: Require in-hospital initiation; TdP risk
6. **β-blockers, CCBs**: First-line for rate control in AF
7. **Adenosine**: Drug of choice for acute PSVT
8. **Magnesium**: Drug of choice for Torsades de pointes
9. **Pro-arrhythmia**: Major concern; all antiarrhythmics can cause arrhythmias
10. **ICD over drugs**: Preferred for sustained VT/VF prevention

---

## References

1. Katzung's Basic & Clinical Pharmacology, 15th Edition
2. Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Edition
3. 2019 AHA/ACC/HRS Focused Update on Atrial Fibrillation
4. 2017 AHA/ACC/HRS Guideline for Management of Ventricular Arrhythmias
5. Vaughan Williams EM. A classification of antiarrhythmic actions. Eur Heart J. 1984.
6. CAST Investigators. Cardiac Arrhythmia Suppression Trial. NEJM 1989, 1991.
